Bone Disease in Multiple Myeloma: Biologic and Clinical Implications
Multiple Myeloma (MM) is a hematologic malignancy characterized by the proliferation of monoclonal plasma cells localized within the bone marrow. Bone disease with associated osteolytic lesions is a hallmark of MM and develops in the majority of MM patients. Approximately half of patients with bone...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-07-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/11/15/2308 |
| _version_ | 1797414315283709952 |
|---|---|
| author | Zachary S. Bernstein E. Bridget Kim Noopur Raje |
| author_facet | Zachary S. Bernstein E. Bridget Kim Noopur Raje |
| author_sort | Zachary S. Bernstein |
| collection | DOAJ |
| description | Multiple Myeloma (MM) is a hematologic malignancy characterized by the proliferation of monoclonal plasma cells localized within the bone marrow. Bone disease with associated osteolytic lesions is a hallmark of MM and develops in the majority of MM patients. Approximately half of patients with bone disease will experience skeletal-related events (SREs), such as spinal cord compression and pathologic fractures, which increase the risk of mortality by 20–40%. At the cellular level, bone disease results from a tumor-cell-driven imbalance between osteoclast bone resorption and osteoblast bone formation, thereby creating a favorable cellular environment for bone resorption. The use of osteoclast inhibitory therapies with bisphosphonates, such as zoledronic acid and the RANKL inhibitor denosumab, have been shown to delay and lower the risk of SREs, as well as the need for surgery or radiation therapy to treat severe bone complications. This review outlines our current understanding of the molecular underpinnings of bone disease, available therapeutic options, and highlights recent advances in the management of MM-related bone disease. |
| first_indexed | 2024-03-09T05:31:05Z |
| format | Article |
| id | doaj.art-38f4cc1f6640410f8ed7779edcd9bf67 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-09T05:31:05Z |
| publishDate | 2022-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-38f4cc1f6640410f8ed7779edcd9bf672023-12-03T12:32:03ZengMDPI AGCells2073-44092022-07-011115230810.3390/cells11152308Bone Disease in Multiple Myeloma: Biologic and Clinical ImplicationsZachary S. Bernstein0E. Bridget Kim1Noopur Raje2Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USADepartment of Pharmacy, Massachusetts General Hospital, Boston, MA 02114, USACenter for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USAMultiple Myeloma (MM) is a hematologic malignancy characterized by the proliferation of monoclonal plasma cells localized within the bone marrow. Bone disease with associated osteolytic lesions is a hallmark of MM and develops in the majority of MM patients. Approximately half of patients with bone disease will experience skeletal-related events (SREs), such as spinal cord compression and pathologic fractures, which increase the risk of mortality by 20–40%. At the cellular level, bone disease results from a tumor-cell-driven imbalance between osteoclast bone resorption and osteoblast bone formation, thereby creating a favorable cellular environment for bone resorption. The use of osteoclast inhibitory therapies with bisphosphonates, such as zoledronic acid and the RANKL inhibitor denosumab, have been shown to delay and lower the risk of SREs, as well as the need for surgery or radiation therapy to treat severe bone complications. This review outlines our current understanding of the molecular underpinnings of bone disease, available therapeutic options, and highlights recent advances in the management of MM-related bone disease.https://www.mdpi.com/2073-4409/11/15/2308multiple myelomadenosumabbone metastasisbisphosphonates: zoledronic acid |
| spellingShingle | Zachary S. Bernstein E. Bridget Kim Noopur Raje Bone Disease in Multiple Myeloma: Biologic and Clinical Implications Cells multiple myeloma denosumab bone metastasis bisphosphonates: zoledronic acid |
| title | Bone Disease in Multiple Myeloma: Biologic and Clinical Implications |
| title_full | Bone Disease in Multiple Myeloma: Biologic and Clinical Implications |
| title_fullStr | Bone Disease in Multiple Myeloma: Biologic and Clinical Implications |
| title_full_unstemmed | Bone Disease in Multiple Myeloma: Biologic and Clinical Implications |
| title_short | Bone Disease in Multiple Myeloma: Biologic and Clinical Implications |
| title_sort | bone disease in multiple myeloma biologic and clinical implications |
| topic | multiple myeloma denosumab bone metastasis bisphosphonates: zoledronic acid |
| url | https://www.mdpi.com/2073-4409/11/15/2308 |
| work_keys_str_mv | AT zacharysbernstein bonediseaseinmultiplemyelomabiologicandclinicalimplications AT ebridgetkim bonediseaseinmultiplemyelomabiologicandclinicalimplications AT noopurraje bonediseaseinmultiplemyelomabiologicandclinicalimplications |